
Natco Pharma marketing partner BPI gets USFDA nod for anti-cancer drug
The Hindu
Drugmaker Natco Pharma’s marketing partner, Breckenridge Pharmaceutical (BPI), has received final approval for its abbreviated new drug application for Everolimus Tablets from the U.S. Food and Drug Administration.
The product is a generic version of Afinitor and indicated in the treatment of breast cancer and a few other types of cancers. BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product within the next few weeks.
More Related News